Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets.
Τίτλος | Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Moschos, M. M., Moustafa G. A., Papakonstantinou V. D., Tsatsos M., Laios K., & Antonopoulou S. |
Journal | Drug Des Devel Ther |
Volume | 11 |
Pagination | 1267-1272 |
Date Published | 2017 |
ISSN | 1177-8881 |
Λέξεις κλειδιά | Adenosine Diphosphate, Arachidonic Acid, Blood Platelets, Glaucoma, Humans, Mediator Complex, Ophthalmic Solutions, Platelet Activating Factor, Platelet Aggregation |
Abstract | PURPOSE: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action.MATERIALS AND METHODS: The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]).RESULTS: Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP- and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (<0.05).CONCLUSION: This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets. |
DOI | 10.2147/DDDT.S131582 |
Alternate Journal | Drug Des Devel Ther |
PubMed ID | 28458520 |
PubMed Central ID | PMC5402915 |